Page 121 - Quantitative Imaging of Small Tumours with Positron Emission Tomography

Chapter 5 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424. 2. Rowe SP, Gorin MA, Allaf ME, et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016;19:223-230. 3. Perner S, Hofer MD, Kim R, et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol. 2007;38:696-701. 4. Perera M, Papa N, Christidis D, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate- specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926-937. 5. Robu S, Schmidt A, Eiber M, et al. Synthesis and preclinical evaluation of novel (18)F-labeled Glu- urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007. EJNMMI Res. 2018;8:30. 6. Chen Y, Pullambhatla M, Foss CA, et al. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)- amino]-pentyl}-ureido)-pen tanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Clin Cancer Res. 2011;17:7645-7653. 7. Fendler WP, Eiber M, Beheshti M, et al. (68)Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014-1024. 8. Gupta M, Choudhury PS, Rawal S, Goel HC, Rao SA. Evaluation of RECIST, PERCIST, EORTC, and MDA criteria for assessing treatment response with Ga68-PSMA PET-CT in metastatic prostate cancer patient with biochemical progression: a comparative study. Nucl Med Mol Imaging. 2018;52:420-429. 9. Seitz AK, Rauscher I, Haller B, et al. Preliminary results on response assessment using (68)Ga-HBED- CC-PSMA PET/CT in patients with metastatic prostate cancer undergoing docetaxel chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:602-612. 10. Jansen BHE, Yaqub M, Voortman J, et al. Simplified methods for quantification of (18)F-DCFPyL uptake in patients with prostate cancer. J Nucl Med. 2019; doi: 10.2967/jnumed.119.227520. 11. Ravert HT, Holt DP, Chen Y, et al. An improved synthesis of the radiolabeled prostate-specific membrane antigen inhibitor, [(18) F]DCFPyL. J Labelled Comp Radiopharm. 2016;59:439-450. 12. Kolthammer JA, Su KH, Grover A, Narayanan M, Jordan DW, Muzic RF. Performance evaluation of the Ingenuity TF PET/CT scanner with a focus on high count-rate conditions. Phys Med Biol. 2014;59:3843-3859. 13. Boellaard R, Delgado-Bolton R, Oyen WJ, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328-354. 14. Tohka J, Reilhac A. Deconvolution-based partial volume correction in Raclopride-PET and Monte Carlo comparison to MR-based method. Neuroimage. 2008;39:1570-1584. 15. Kaalep A, Sera T, Rijnsdorp S, et al. Feasibility of state of the art PET/CT systems performance harmonisation. Eur J Nucl Med Mol Imaging. 2018;45:1344-1361. 16. Jansen BHE, Kramer GM, Cysouw MCF, et al. Healthy Tissue Uptake of (68)Ga-Prostate Specific Membrane Antigen (PSMA), (18)F-DCFPyL, (18)F-Fluoromethylcholine (FCH) and (18) F-Dihydrotestosterone (FDHT). J Nucl Med. 2019;60(8):1111-1117. 17. Boellaard R. Quantitative oncology molecularanalysis suite: ACCURATE May 1st, 2018 ed: J Nucl Med; 2018;59 Suppl 1:1753. 18. Frings V, Yaqub M, Hoyng LL, et al. Assessment of simplified methods to measure 18F-FLT uptake changes in EGFR-mutated non-small cell lung cancer patients undergoing EGFR tyrosine kinase inhibitor treatment. J Nucl Med. 2014;55:1417-1423. 19. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122s-150s. 20. Pitman E. A note on normal correlation. Biometrika. 1939;31:9-12. 21. Holm S. A simple sequentially rejective multiple test procedure. Scandinavian journal of statistics. 1979:65-70. 120